Abstract：
Prostate cancer is the most commonly diagnosed cancer in American men and 2nd leading cause of cancer-related deaths in the United States. Androgen deprivation therapy (ADT) is the backbone of treatment for advanced prostate cancer. Over the past several decades a number of new therapeutics, such as novel androgen receptor pathway inhibitors, targeted agents and radionuclide therapies, have been introduced for the treatment of prostate cancers. These agents have been demonstrated to improve clinical outcomes of prostate cancer patients in randomized clinical trials. In addition, new therapeutic strategies, such as early intensification of ADT, novel treatment combinations, and treatment sequencing, are expected to improve outcomes further. In this clinical review, we discuss the changing treatment landscape for advanced prostate cancer with a focus on new therapeutics.
摘要：
前列腺癌是美国男性中最常见的癌症，也是美国癌症相关死亡的第二大原因。雄激素剥夺疗法（ADT）是晚期前列腺癌治疗的支柱。在过去的几十年里，一些新的疗法，如新型雄激素受体途径抑制剂，靶向药物和放射性核素治疗，已被用于治疗前列腺癌。在随机临床试验中，这些药物已被证明可以改善前列腺癌患者的临床结果。此外,新的治疗策略，例如ADT的早期强化，新的治疗组合，和治疗顺序，预计将进一步改善结果。在这篇临床综述中，我们讨论了晚期前列腺癌治疗的变化，重点是新疗法。
